MARKET

TNDM

TNDM

Tandem Diabetes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

89.96
-3.58
-3.83%
After Hours: 89.96 0 0.00% 16:56 03/03 EST
OPEN
93.89
PREV CLOSE
93.54
HIGH
93.89
LOW
88.34
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
123.74
52 WEEK LOW
43.69
MARKET CAP
5.62B
P/E (TTM)
-155.8289
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Tandem Diabetes Care (NASDAQ:TNDM) Has Debt But No Earnings; Should You Worry?
Simply Wall St. · 1d ago
Is Tandem Diabetes Care (TNDM) Stock a Buy For 2021?
Insider Monkey · 2d ago
Tandem names Jordan Pinsker Vice President and Medical Director
Tandem Diabetes Care ([[TNDM]] -0.4%) announces the appointment of Jordan Pinsker to Vice President and Medical Director, effective April 26, 2021.Pinsker is a leading pediatric endocrinologist and joins Tandem from Sansum Diabetes Research Institute,
Seekingalpha · 2d ago
Tandem Diabetes Care Appoints Leading Artificial Pancreas Researcher Dr. Jordan Pinsker as Medical Director
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jordan Pinsker, MD, to Vice President and Medical Director, effective April 26, 2021.
BusinessWire · 2d ago
Tandem Diabetes Surpasses 4Q Estimates; Shares Rise 4%
Tandem Diabetes Care delivered a stronger-than-expected 4Q performance, driven by a 67% jump in its global pump shipments. Shares of the insulin delivery and diabetes technology company were up about 4% at end of trading on Feb. 25. Tandem Diabetes (TNDM) ...
SmarterAnalyst · 5d ago
Best Stocks To Buy Now? 4 Tech Stocks To Watch
Feb 25, 2021 (StockMarket.com via COMTEX) -- Making A List Of The Best Tech Stocks To Watch Right Now? 4 To Consider Tech stocks are back in focus once again...
StockMarket.com · 6d ago
Robert W. Baird Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)
Robert W. Baird analyst Jeff Johnson maintained a Hold rating on Tandem Diabetes Care (TNDM) today. The company's shares closed last Thursday at $99.34.
SmarterAnalyst · 6d ago
Tandem Diabetes shares rise on strong Q4 topline beat
Tandem Diabetes ([[TNDM]] +6.6%) reported fourth-quarter revenue that beat Wall Street estimates, helped by the surge in worldwide pump shipments during the quarter.Worldwide pump shipments increased 67% to 32,685 pumps,
Seekingalpha · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TNDM. Analyze the recent business situations of Tandem Diabetes through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TNDM stock price target is 127.67 with a high estimate of 150.00 and a low estimate of 99.00.
EPS
Institutional Holdings
Institutions: 500
Institutional Holdings: 65.96M
% Owned: 105.53%
Shares Outstanding: 62.50M
TypeInstitutionsShares
Increased
110
6.31M
New
105
1.82M
Decreased
103
4.86M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.37%
Healthcare Equipment & Supplies
-2.63%
Key Executives
Chairman/Director
Kim Blickenstaff
President/Chief Executive Officer/Director
John Sheridan
Chief Financial Officer/Executive Vice President/Treasurer
Leigh Vosseller
Executive Vice President/Chief Administrative Officer
Susan Morrison
Executive Vice President/Chief Compliance Officer/Secretary
David Berger
Executive Vice President
Elizabeth Gasser
Executive Vice President
Brian Hansen
Lead Director/Independent Director
Dick Allen
Director
Rajwant Sodhi
Independent Director
Edward Cahill
Independent Director
Peyton Howell
Independent Director
Kathleen McGroddy-Goetz
Independent Director
Rebecca Robertson
Independent Director
Douglas Roeder
Independent Director
Christopher Twomey
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About TNDM
Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.

Webull offers kinds of Tandem Diabetes Care Inc stock information, including NASDAQ:TNDM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNDM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNDM stock methods without spending real money on the virtual paper trading platform.